These findings thus strongly suggest that upregulated MCL-1 could play a restrictive role on SRF231/CD47 blockade-induced necroptosis and that venetoclax should not be used with SRF231 in settings where cancer cells do not depend on BCL-2 for survival. Here, BCL2 is linked to cancer.